Question explored with the scientific record
What is the current status of using GLP 1 medications to treat substance abuse?
The short version: no trial has yet shown that a GLP-1 drug helps anyone quit a drug of abuse. What exists is a mechanism story, animal data, and a large observational correlation.
The strongest human number is a retrospective cohort of about 1.96 million VA patients, where GLP-1 users had modestly lower rates of substance use disorder than users of other diabetes drugs: hazard ratios around 0.84 to 0.89 for stimulants, alcohol, cannabis, and opioids, and reduced suicidal ideation [1]. Two things must be said about that. It is a correlation, not an experiment [1]. And it compares treated to treated, so it cannot separate the drug from who gets prescribed it. The real test, a randomized trial against placebo, is only now being launched: an ongoing phase 2 protocol plans 200 people with opioid use disorder, testing semaglutide against placebo, with urine-confirmed abstinence as the primary outcome and results not yet published [2].
The mechanism is plausible. GLP-1 receptors sit in the brain's reward circuit, and animal studies show reduced dopamine release and less drug-seeking for alcohol, nicotine, cocaine, and opioids [5]. That is a hypothesis, not a proven effect in people.
| Evidence layer | What it shows |
|---|---|
| Retrospective VA cohort (1.96M) | Lower SUD rates, treated-vs-treated, not causal [1] |
| Randomized trial protocol | 200 patients, placebo-controlled, at three US sites; no results yet [2] |
| Animal models | Reduced drug-seeking across substances [5] |
| Cost | GLP-1 drugs not cost-effective at current US net prices [6] |
My call: promising but unproven for substance use, and nobody should be told it treats addiction until the placebo-controlled trials report. Confidence: moderate.
Side effects seen in these drug classes run to stomach upset, and pancreatitis risk is the flag to watch; the retrieved safety data are about diabetes and weight, not addiction treatment [3][4][6].
Sources used 6
-
GLP-1 Receptor Agonists as a Novel Solution for Antipsychotic-Induced Weight Gain in Severe and Persistent Mental Illness
This article reviews and synthesizes evidence on using GLP-1 receptor agonists to address antipsychotic-induced weight gain in severe and persistent mental illness, highlighting notable weight loss in schizophrenia with clozapine treatment (COaST trial), supportive case-series/c…
DOI: 10.1177/07067437251386626 -
Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with OUD: a randomized, double-blind, placebo-controlled clinical trial protocol
A phase II randomized, double-blind, placebo-controlled trial protocol to evaluate whether once-weekly semaglutide (GLP-1 receptor agonist) increases abstinence from illicit/nonprescribed opioids and reduces craving in adults with opioid use disorder who remain positive for nonp…
DOI: 10.1186/s13722-025-00618-2 -
Efficacy of GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists in managing MALFD: a meta-analysis of randomized controlled trials
A comprehensive systematic review and meta-analysis of 26 randomized controlled trials (3,453 participants with metabolic dysfunction-associated fatty liver disease, MAFLD) showing that GLP-1 receptor agonists, especially dual GLP-1/GIP agonists, improve hepatic and metabolic ou…
DOI: 10.1186/s12876-025-04358-0 -
Risk of recurrent acute pancreatitis with GLP-1 receptor agonists after prior pancreatitis: a systematic review
Across four studies of 10,624 adults with prior acute pancreatitis, GLP-1 receptor agonist use was not associated with an apparent increase in recurrent acute pancreatitis, though comparative evidence came from only two studies.
DOI: 10.1007/s00592-026-02809-y -
Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological and Translational Insights
This review synthesizes preclinical and clinical evidence that glucagon-like peptide-1 receptor agonists (GLP-1RAs) modulate mesocorticolimbic reward circuits via gut-brain signaling and synaptic plasticity to reduce craving and substance-seeking behaviors across alcohol, nicoti…
DOI: 10.3390/medsci13030136 -
Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults
A lifetime cost-effectiveness analysis using the Diabetes, Obesity, Cardiovascular Disease Microsimulation (DOC-M) model compared four antiobesity medications (tirzepatide, semaglutide, naltrexone-bupropion, phentermine-topiramate) plus lifestyle modification versus lifestyle mo…
DOI: 10.1001/jamahealthforum.2024.5586